A Study of PTS100 in Primary HCC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 19, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Para-Toluenesulfonamide

A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is assigned as 30% of TTV for each patient and maximum TTV should be less than 366 cm3.

Trial Locations (3)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Medical University Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

Gongwin Biopharm Co., Ltd.

INDUSTRY